Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
BACKGROUND: Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma (UC).
METHODS: We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC.
RESULTS: Serial ctDNA-derived metrics predicted the clinical outcomes in patients with advanced UC. Combining serial ctDNA aggregate VAF (aVAF) values with clinical factors, including age, sex, and liver metastasis, improved the performance of prognostic models. An increase of the ctDNA aVAF by ≥1 in serial ctDNA samples predicted disease progression within 6 months in 90% of patients. The majority of patients with aVAFs ≤0.7 in three consecutive ctDNA samples achieved durable clinical responses (≥6 months).
CONCLUSIONS: Serial ctDNA analysis predicts disease progression and enables dynamic monitoring to guide precision medicine in patients with advanced UC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:126 |
|---|---|
| Enthalten in: |
British journal of cancer - 126(2022), 3 vom: 19. Feb., Seite 430-439 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shohdy, Kyrillus S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 22.02.2022 Date Revised 04.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41416-021-01648-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335812031 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335812031 | ||
| 003 | DE-627 | ||
| 005 | 20231225230718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-021-01648-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335812031 | ||
| 035 | |a (NLM)35046520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shohdy, Kyrillus S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2022 | ||
| 500 | |a Date Revised 04.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a BACKGROUND: Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma (UC) | ||
| 520 | |a METHODS: We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC | ||
| 520 | |a RESULTS: Serial ctDNA-derived metrics predicted the clinical outcomes in patients with advanced UC. Combining serial ctDNA aggregate VAF (aVAF) values with clinical factors, including age, sex, and liver metastasis, improved the performance of prognostic models. An increase of the ctDNA aVAF by ≥1 in serial ctDNA samples predicted disease progression within 6 months in 90% of patients. The majority of patients with aVAFs ≤0.7 in three consecutive ctDNA samples achieved durable clinical responses (≥6 months) | ||
| 520 | |a CONCLUSIONS: Serial ctDNA analysis predicts disease progression and enables dynamic monitoring to guide precision medicine in patients with advanced UC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 700 | 1 | |a Villamar, Dario M |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Trieu, Janson |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Kristin S |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Tagawa, Scott T |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Sternberg, Cora N |e verfasserin |4 aut | |
| 700 | 1 | |a Nanus, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Mosquera, Juan Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Elemento, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Sonpavde, Guru P |e verfasserin |4 aut | |
| 700 | 1 | |a Grivas, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Vogelzang, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Faltas, Bishoy Morris |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 126(2022), 3 vom: 19. Feb., Seite 430-439 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:126 |g year:2022 |g number:3 |g day:19 |g month:02 |g pages:430-439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-021-01648-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 126 |j 2022 |e 3 |b 19 |c 02 |h 430-439 | ||